Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corporation plc (AMRN) CEO John Thero Presents at Piper Sandler 32nd Annual Virtual Healthcare Conference Call - (Transcript)

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today the filing of a patent infringement lawsuit by Amarin affiliates and a licensor against Hikma Pharmaceuticals PLC and Hikma's U.S. affiliate. The lawsuit was filed in the United States District Court in Delaware. A copy of the complaint is available in the FAQ section of Amarin's investor relations website.

Amarin Files Patent Infringement Lawsuit Against Hikma

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to participate in a Fireside Chat at the Piper Sandler's 32nd Annual Healthcare Conference (Virtual) taking place from December 1 - December 3, 2020. Mr. Thero's presentation is scheduled to take place on Wednesday, December 2, 2020 at 10:00 am Eastern time.

Amarin to Present at Piper Sandler's 32nd Annual Healthcare Conference (Virtual)

Amarin lost its generic appeal and the stock has faltered badly. People are possibly ignoring the vast European market and also what's left of the US market may be protected by manufacturing hurdles.

Amarin: There's Still Some Fight Left In This Stock

Amarin's legal loss at the U.S. appeals court sent the stock lower. Positive clinical data from China partner a catalyst.

Buy Amarin And Bet On Its Recovery In 2021

After Amarin lost its patent rights in the U.S., the stock crashed overnight. Investors might want to stay optimistic.

Amarin vs. the Generics: Who Will Win?

AMRN stock is climbing higher Thursday thanks to good news from a clinical trial in China. Here's what you should know about Amarin now.

AMRN Stock News: Why Amarin Shares Are Climbing Today

Significant Reduction in Triglyceride Levels Without Low-Density Lipoprotein Cholesterol ( LDL-C ) Increase Compared to Placebo and Safety Profile Similar to Placebo Achieved with 4 Grams Per Day Dose of Icosapent Ethyl in Chinese Patients with Very High Triglycerides ( > 500 mg/dL)

Amarin Shares Topline Data from Partner's Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China

Amarin Corporation PLC (AMRN) Presents at Jefferies Virtual London Healthcare Broker Conference Call - (Transcript)

Findings further support the differentiated multifactorial mechanism of action of VASCEPA and its robust clinical effective ness in reducing major adverse cardiovascular events (MACE) in studied high-risk patients

Multiple New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at American Heart Association's Virtual Scientific Sessions 2020

Amarin Corporation plc (AMRN) Presents at Stifel Virtual Healthcare Conference (Transcript)

VASCEPA®, compared with placebo, significantly reduced primary composite first and total major adverse cardiovascular events ( MACE ) in post hoc exploratory analyses of patients with a history of CABG by 2 4% and 3 6 %, respectively, and key secondary composite first hard MACE, comprised of heart attacks, stroke and cardiovascular death, by 3 1 %

VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting (CABG) Procedures in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Association's Virtual 

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present general company updates at the following investor conferences scheduled in November:

Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences

Amarin's (AMRN) revenue growth in the third quarter is attributable to continued demand for its cardiovascular drug, Vascepa. Generic competition for Vascepa seems imminent.

Amarin's (AMRN) Q3 Earnings Lag, Sales In Line, Stock Down

Amarin Corporation plc (AMRN) CEO John Thero on Q3 2020 Results - Earnings Call Transcript

Total Revenue Increased 39 % in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared to Same Periods of 2019 Despite COVID-19 Headwinds

Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update

Tesla

Zoom Video

Here's why the stock prices of Tesla, Zoom, and Amarin are being driven by overexuberant speculation.

These 3 Stocks Are Trading at Ludicrous P/E Ratios. Should Investors Avoid Them?

The heart drug continues to test well in clinical trials.

Amarin's Vascepa Shows Reduced Cardiovascular Events in Kidney Patients in Latest Study

Patients with decreased renal function prior to treatment with VASCEPA or placebo had higher rates of cardiovascular events than the overall population studied in REDUCE-IT

VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Cardiovascular Events in Patients with Compromised Renal Function at Baseline in Prespecified and Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Society of Nephrology 

New analysis of contemporary real-world data presented at American Society of Nephrology (ASN) Kidney Week 2020 New analysis of contemporary real-world data presented at American Society of Nephrology (ASN) Kidney Week 2020

U.S. Veterans with Decreased Renal Function Shown to Be at Higher Risk for Adverse Cardiovascular Events if They Have Moderately Elevated Triglyceride (TG) Levels Despite Well-Controlled Low-Density Lipoprotein (LDL)-Cholesterol

Alexion Pharma

BioMarin Pharmaceutical

The health care strategy analyst at Jefferies said he expects to see acquisitions in the pharma and biotech space in the $5 billion to $10 billion range, according to an article in FierceBiotech. The publication enlisted the help of Jeffries' Jared Holtz to compile a list of the 10 top industry takeover targets.

Analyst's Potential Buyout List Includes Alexion, Amarin and Biomarin

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's third quarter 2020 financial results and provide an operational update on Thursday, November 5, 2020, at 7:30 a.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day.

Amarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020

Galapagos

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 15)

The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs

VASCEPA ® , c ompared with placebo, significantly reduced primary composite first and total MACE (m ajor a dverse c ardiovascular e vents ) in post hoc exploratory analyses of patients with a history of PCI by 34% and 39% , respectivel y, and k ey secondary composite first hard MACE , comprised of heart attacks, stroke and cardiovascular death, by 34%

VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Intervention (PCI) in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at Transcatheter Cardiovascular Therapeutics (TCT

Clean Energy Fuels

The stocks of Amarin and Clean Energy Fuels are down 90% off their highs -- but both could bounce back in a big way.

News for Amarin Corporation Plc Stock (AMRN)